NRI

NRI (New Receptor Inhibitor of IL-6) is an experimental recombinant biologic agent developed by researchers at Saga University in collaboration with Chugai Pharmaceutical. It is a humanized anti-interleukin-6 receptor (IL-6R) agent engineered from the monoclonal antibody tocilizumab. The structure of NRI consists of a single-chain variable fragment (scFv) derived from the VH and VL regions of tocilizumab, which is dimerized by fusion to the Fc portion of human immunoglobulin G1 (IgG1). This single-gene design was specifically optimized for delivery via gene therapy vectors, such as adenovirus (Ad/CMV/NRI). NRI functions as an IL-6R antagonist, blocking the binding of IL-6 and inhibiting downstream signaling pathways critical for the progression of inflammatory diseases and certain malignancies. Preclinical studies have demonstrated its efficacy in inhibiting the growth of IL-6-dependent cell lines, such as multiple myeloma and Lennert's lymphoma, and achieving sustained therapeutic serum levels in mouse models following intraperitoneal administration.

Other names

New Receptor Inhibitor of IL-6Ad/CMV/NRI